Moderna and Merck Set to Reveal Key Cancer Vaccine Trial Results

2026-10-23 companies

Boston, Thursday, 22 October 2026.
Full Phase 3 trial data for a personalized melanoma vaccine will be presented in Madrid, highlighting a potential treatment breakthrough despite ongoing six-week manufacturing challenges.

Upcoming Data Reveal at ESMO 2026

Moderna (NASDAQ: MRNA) and Merck & Co. (NYSE: MRK) are preparing to present full Phase 3 clinical trial results for their personalized mRNA cancer vaccine at the European Society for Medical Oncology (ESMO) congress in Madrid [1][2]. The highly anticipated data reveal is scheduled to occur in the coming days, with the presentation specifically set for October 24, 2026 [1][6]. This event marks a critical milestone for the commercial viability of individualized mRNA therapeutics, with company leadership signaling expectations for significantly streamlined manufacturing timelines in the future [1][3]. Positive results from this trial could catalyze a major shift in oncology treatment paradigms and secure a new long-term growth driver for both pharmaceutical giants [2].

Clinical Efficacy and Trial Details

The experimental vaccine, known as intismeran autogene (V940), is designed to target up to 34 neoantigens from a patient’s unique tumor mutations [3]. The Phase 3 INTerpath-001 clinical trial enrolled 1,137 participants with stage IIB to IV cutaneous melanoma that was surgically removed and had not received prior systemic therapy [4]. Results announced in August 2026 showed the combination of the vaccine and Merck’s immunotherapy drug Keytruda (pembrolizumab) significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone [3][4]. Prior Phase 2b data from the KEYNOTE-942 trial involving 157 patients indicated a 49% relative reduction in the risk of cancer recurrence or death when using the vaccine combined with Keytruda compared to Keytruda alone [3][4].

Manufacturing Challenges and Market Response

Despite the clinical promise, the current manufacturing process for the personalized vaccine takes approximately six weeks, involving genetic sequencing, messenger RNA treatment design, and quality checks [3]. To support potential commercial launch capabilities, Tempus announced an expanded multiyear collaboration with Merck and Moderna on October 7, 2026, to manage tumor tissue and blood sample collection [3]. In market reactions ahead of the data release, Moderna shares rose 7% to $241.89 on October 19, 2026 [6]. While the companies intend to file for FDA review following positive Phase 3 trial results, no specific filing date has been announced [4][5].

Sources

Biotechnology Oncology